Purpose This study reviews FDA-approved drugs that negatively impact spermatozoa in animals, as well as how these findings reflect on observations in human male gametes. Methods The FDA drug warning labels included in the DailyMed database and the peer-reviewed literature in the PubMed database were searched for information to identify single-ingredient, FDA-approved prescription drugs with spermatotoxic effects. Results A total of 235 unique, single-ingredient, FDAapproved drugs reported to be spermatotoxic in animals were identified in the drug labels. Forty-nine of these had documented negative effects on humans in either the drug label or literature, while 31 had no effect or a positive impact on human sperm. For the other 155 drugs that were spermatotoxic in animals, no human data was available. Conclusion The current animal models are not very effective for predicting human spermatotoxicity, and there is limited information available about the impact of many drugs on human spermatozoa. New approaches should be designed that more accurately reflect the findings in men, including more studies on human sperm in vitro and studies using other systems (ex vivo tissue culture, xenograft models, in silico studies, etc.). In addition, the present data is often incomplete or reported in a manner that prevents interpretation of their clinical relevance. Changes should be made to the requirements for pre-clinical testing, drug surveillance, and the warning labels of drugs to ensure that the potential risks to human fertility are clearly indicated.
Introduction
It has been estimated that approximately 5-10% of men in developed countries are affected by infertility due to abnormalities in spermatozoa (number, morphology, motility, etc.) or semen (volume, composition, viscosity, etc.) [1] . There are numerous causes, including genetics, hormone imbalances, dietary insufficiencies, exposure to environmental or occupational toxicants, or the use/abuse of drugs (recreational, overthe-counter, or prescription). Given that approximately half of the US population has taken a prescription drug in the last month [2] , prescription drugs may represent a common source of spermatotoxicity.
The present review focuses on the spermatotoxic effects (from the generation of spermatogonia to fertilization) of prescription drugs in various experimental animals. This review was prompted by a previous publication that examined the impact of FDA-approved drugs on human spermatogenesis [3] . In that study, frequent discrepancies were noted in the drug warning labels between the adverse effects of drugs on human and animal spermatogenesis, as well as some inconsistencies between the published peer-reviewed literature and the DailyMed database (a federal repository of drug warning Elizabeth R. Rayburn and Liang Gao should be considered joint first authors. labels). In addition to providing an overview of the spermatotoxicity of prescription drugs in animals, the review also provides a comparison to the reported human spermatotoxicity and addresses how the current data reflect the risk of these drugs to human sperm. This review also suggests ways to improve the current male reproductive toxicity testing and reporting of results.
Materials and methods

Database search and inclusion/exclusion criteria
The FDA indicates that any finding of toxicity should be reported on the drug labels in the BWarnings,^BAdverse Reactions,^and BPrecautions^sections, as well as any other area where such a warning would be appropriate. The DailyMed database (http://dailymed.nlm.nih.gov/dailymed/ index.cfm) is a federal database that contains approximately 85% of the US FDA-approved drug labels. This database represents the largest and most comprehensive database of the warning labels for FDA-approved drugs and is updated whenever a label changes.
Stemmed key words were used to search the full-text drug labels included in the DailyMed database (also availa bl e a t : h t t p s : / / w w w. f d a . g o v /Sci en ce Res ea rc h/ BioinformaticsTools/ucm289739.htm) as described in a previous study [4] . These stemmed keywords (deferen, epidid, interstitial, Leydig, semen, semin, Sertoli, sperm, an d t esti) cov ered nume rou s t erms re lated t o spermatogenesis, pathological changes of the male reproductive organs (such as testicular tumors, testitis, and epididymitis), and direct effects on the spermatozoa. To ensure that the effects were due to the specific drugs, drugs with indirect effects on sperm (i.e., drugs with teratogenic effects impacting the fertility of male offspring) were excluded. Only FDA-approved prescription drugs developed for administration to humans were examined. Over-the-counter (OTC) drugs were excluded because the information available on their labels was generally insufficient and most have not been subjected to rigorous reproductive toxicity testing. The drugs with multiple active ingredients were also excluded to reduce the complexity of the analysis. When there were redundant labels for drugs produced by different companies or drugs with more than one label that had been updated at different times, only the most recent label was analyzed. Other labels for drugs intended for veterinary use, medicinal foods, medical devices, dietary supplements, cosmetics, etc., were also excluded. When the final stemmed keyword search was performed on August 8, 2017 , there were 95,873 labels included in the DailyMed database. After restricting the information to single-ingredient drugs as described above, a total of 251 unique prescription drug labels were identified that showed a negative impact on sperm, which were further narrowed down to 235 drugs because some of them were the same drug in different formulations that led to the same adverse effects (i.e., aripiprazole/aripiprazole lauroxil).
Data extraction and analysis
Two authors independently searched the DailyMed database and extracted relevant data. When there were differences in the descriptions extracted between these authors, they discussed the findings with additional authors, and the group's consensus regarding the findings was used for the analysis.
A PubMed search was also performed to determine whether animal or human toxicity had been reported for the 235 drugs identified to impact animal spermatogenesis based on the DailyMed labels. The PubMed database was searched using the terms ([generic drug name] AND sperm*, fertil*, semen, semin*, or testi*).
Results
The general findings of the database searches A total of 235 FDA-approved drugs intended for human use and containing a single active ingredient were found to impact spermatogenesis in at least one type of animal. All of these drugs could result in a decrease in the sperm count/ concentration or a decrease in sperm quality, viability, or fertilization capacity.
Rats were the model most often reported to be affected by the drugs (specifically reported for 184 of the 235 drugs). This was expected, because rats are the most commonly used animal model for reproductive toxicity testing. Dogs are often used to confirm the findings in rats, and were thus also frequently reported to experience changes in spermatogenesis due to the exposure to prescription drugs. There were many instances where only rats were listed as having changes in spermatogenesis following drug exposure, either because there was no toxicity in other animals or because confirmation testing was not performed. Interestingly, in about half of the cases, spermatotoxicity was only reported for dogs. This suggests that dogs may be particularly sensitive to spermatotoxicants. Only 34 of the 235 drugs were reported to affect primate spermatogenesis. However, it is likely that many of the drugs were not tested in primates given the ethical concerns and high expenses associated with testing in primates. In addition, although spermatotoxicity was reported for 11 other drugs in DailyMed, the type of animal(s) affected was not specified in the drug label.
The FDA-approved drugs reported to adversely affect animal spermatogenesis Unsurprisingly, antineoplastic agents were the category of drugs most often reported to have effects on animal spermatogenesis. Antineoplastic agents can cause temporary or permanent damage to the spermatozoa, germ cells, or support cells. Hormones and hormone antagonists were also expected to have adverse effects on spermatogenesis, so it is not surprising that they make up the other category of drugs most frequently noted to be spermatotoxic in this study. Both classes of drugs are well-recognized as having a potential negative impact on male fertility, and protocols are in place in most hospitals and clinics to counsel patients about these effects and the means to preserve spermatozoa for future use.
On the other hand, there were numerous other drugs with unexpected spermatotoxicity, where the intended target/ mechanism of action is not generally considered to impact sperm. These drugs were from various classes, including adrenergic agents (icatibant, silodosin), analgesics (carbamazepine, morphine), antihypertensive agents (tamsulosin, reserpine), anti-infectious agents (metronidazole, miconazole), cardiovascular agents (bosentan, spironolactone), and immunosuppressants (sirolimus, azathioprine). Such agents are of greater concern because the adverse effects of these agents on fertility are not well-recognized and may not be addressed when the drugs are prescribed.
The types of spermatotoxic effects reported for animals
The most common adverse effect of the drugs was a reduced sperm count (due to reduced spermatogenesis or the death of developed and developing sperm), followed by reduced sperm motility, abnormal sperm morphology, testicular atrophy, and tumor formation (most frequently benign Leydig cell tumors in rodents). Similar observations of reduced sperm counts, reduced motility, and abnormal sperm morphology have been noted in humans for some of these drugs (see Table 1 ). In contrast to animal studies, where drug-related tumor formation was relatively common, drug-induced testicular tumors seem to be rare in humans. While some agents, such as anabolic steroids, are considered to cause testicular atrophy in men [44] , the histological findings are generally not available, except for rare cases of injury or malignancy that require surgery. This makes it difficult to assess the full extent of the changes in humans.
Of note, most of the reports of adverse effects did not specify how many (what percentage) of the animals were affected. Therefore, it is unclear whether the observed adverse effect was common or relatively rare. The reporting was similarly vague for human effects, with many labels failing to indicate what percentage of the population was affected by the specific type of toxicity.
PubMed findings of human effects for these drugs
Only about 11% (26/235) of the drug warning labels that indicated that the agent had a negative impact on animal sperm (any aspect of spermatogenesis or toxicity to the sperm themselves) also had information in the drug label about a negative effect in humans. There were reports of adverse effects on human sperm for another 36 of these drugs in the PubMed database, although some of these publications were of in vitro studies, case studies, or studies of drug combinations that included the drug of interest (Table 1) . Thus, between the drug labels in DailyMed and the reports included in PubMed, less than 30% of the drugs found to adversely affect animal sperm have been found to adversely affect human sperm.
For about half of the drugs that cited a negative impact on animal sperm, there were no data in DailyMed or PubMed about their impact on human sperm ( Table 2) . Eleven of the drugs without any publications in PubMed indicated that they had effects in humans in the DailyMed labels, although specific details were generally lacking regarding the number of patients affected. Interestingly, there were 33 drugs indicated to have negative effects in animals that were shown to have no effect or a positive impact on human sperm in the published literature (Table 3) .
Discussion
The status of spermatotoxicity testing and relevance of the current testing
Testing for and reporting spermatotoxicity
The guidelines for industry issued by the FDA for new drug development stipulate that B…reproductive or developmental toxicity, whether in valid reproductive/developmental or other relevant nonclinical studies, should be evaluated to estimate the likelihood or other reproductive or developmental risk for humans^. In addition, the BFemales and Males of Reproductive Potential^section requires the inclusion of information when there are human and/or animal data suggesting drug-associated effects on fertility and/or preimplantation loss effects ( §201.57(c)(9)(iii))^ [102] . The FDA, as well as the US Environmental Protection Agency, Occupational Safety and Health Administration, and other national and international organizations, have made efforts to both streamline testing and make the testing as accurate as possible, specifically taking into consideration the route, dose, frequency, and duration of exposure, as well as species-associated differences. The guidelines also emphasize the need to understand the potential impact of drugs on fertility via both pre-clinical studies in animals and subsequent studies in patients, with an [42] understanding that there are some inherent disadvantages associated with testing in animals [103] . Despite the various considerations made to improve the testing process and provide the best predictions of toxicity, there have been numerous studies that reported a lack of efficacy for toxicity testing, including reproductive toxicity testing [104] [105] [106] [107] . In a previous study, a total of 65 labels for single-ingredient FDA-approved drugs were found in DailyMed that indicated that the drugs had a negative impact on human spermatogenesis [3] . In agreement with our present findings suggesting that animal studies have limited predictive power for human spermatotoxicity, fewer than half of the drug labels (26 of 65) indicated that they had effects on animal spermatogenesis. There was support in the literature for an additional six drugs affecting animal spermatogenesis, but this means that approximately half of the prescription drugs that negatively affect human spermatogenesis did not have an animal correlate reported in either the drug label or the peerreviewed literature. This may reflect the inadequacy of the animal model(s) tested, insufficient testing, and/or ineffective reporting of the findings of animal studies.
The relationship between the reported effects in animals and the effects in humans
In the present study, approximately 17% of the single-ingredient, FDA-approved, clinically prescribed drugs included in the DailyMed database (235/1318) had an adverse effect on spermatogenesis in at least one animal. Less than 30% of these drugs have been reported to adversely affect human sperm (in either the drug warning label or the published literature included in PubMed). However, this finding does not indicate that the Bfalse positive^rate of animal toxicity testing is > 70%, because there were no data in either database about the impact of more than half of the drugs on human sperm (see Table 2 ). Therefore, the Bfalse positive^rate for animal testing of the drugs with reported findings was about 35% (33/93) .
Interestingly, of the 33 drugs indicated to have negative effects in animals that were shown to have no effect or a positive impact on human sperm in the literature (Table 3) , four had data in their FDA labels (included in the DailyMed database) indicating that they had a negative impact on human sperm. Since the DailyMed database is supposed to contain up-to-date information, it is possible that new data had been generated since the PubMed studies were published demonstrating the negative effect reported in the label.
It is also possible that there were differences in the experimental conditions (different ages of subjects, subjects of different ethnicities, subjects with different background diseases or stages of disease, or different timing of sample collection after administration, etc.), and these could have led to the different results. Because details were not present in the FDA labels included in the DailyMed database, it is unknown PubMed data based on studies of combination therapy, no data exist for the agent administered alone in humans why there were conflicting data. These findings illustrate the difficulties associated with reproductive toxicity testing. Moreover, they demonstrate the need for better recordkeeping and transparency in terms of the data generated, because it is very difficult to interpret the findings in the drug labels based on the data available.
Difficulties associated with animal testing for spermatotoxicity
The current reproductive toxicity testing should be able to provide useful results for clinical extrapolation. However, as noted above, our current study and previous studies about spermatotoxicity [3, 105, 106] have shown that studies in animals have relatively low predictive value for human toxicity. In some cases, the lack of useful findings is due to the high doses of the compounds used in the toxicity studies. Nevertheless, even if the dose is proper in terms of the allometric scaling for animals based on body surface area (~12× the human dose (mg/kg b.w.) for a mouse,~2× for a dog, etc.
[108]), the plethora of differences between humans and animals reduces the utility of the findings. For example, the pharmacokinetics and pharmacodynamics of drugs may not be similar between the animal model and humans, there may be organ/tissue-related differences that make it impossible to adequately predict or extrapolate the effects, and there may be other fundamental differences between species that abrogate the utility of testing [106] . This is particularly relevant for spermatotoxicity studies, where there are many important differences between rodents and humans, including the time required for spermatogenesis, the development of Leydig cell tumors, and the relative number of sperm produced [109] [110] [111] [112] . Additional Buncertainty^factors have been used when extrapolating human toxicity from animal findings for occupational and environmental toxicants (i.e., when determining the benchmark dose or the acceptable daily intake based on the no observed adverse effects level (NOAEL) [113] , but these types of studies are not usually employed as part of therapeutic drug testing and would be subject to the same issues described above.
Changes that should be made to the testing and reporting of spermatotoxicity
The most important findings of the present study include the following: only 27% (63/235) of the drugs that had a negative effect in animals reported in the drug label were found to have a documented negative impact on human sperm (in the drug labels or literature). Further, a previous study [3] showed that fewer than half of the drugs with labels indicating that they adversely affected human sperm had similar findings in animals. In addition, for more than half of the drugs found to negatively affect animal spermatogenesis or spermatozoa, Based on small studies of < 10 patients, including case studies c Based on studies of combination treatment the impact in humans is unclear either because no testing or surveillance has been performed, or because the results have not been reported. Even in cases where there was clear reporting of the type of human spermatotoxicity and the number of individuals affected, the data were frequently unclear regarding whether the effects were reversible and how long it took to recover potency. These findings suggest that the current system is not performing well and there is a need for better models, different types of pre-clinical testing, different endpoints, and a better system (and/or different regulations) for reporting data. It should be noted that most of the general methods used to assess reproductive toxicity were often developed more than 50 years ago, although there have been updates in terms of automation and some of the details (i.e., sub-types of sperm motility) of the analyses. Our data add to the already extensive body of evidence that animal testing (certainly for spermatotoxicity, but also for many other types of toxicity) is not adequate to predict human risk. However, completely retiring the rat is not possible, at least at present. There are currently no other models that provide better predictive value for the various steps of reproduction. Direct testing on human sperm samples is useful and should be implemented whenever possible, but cannot identify changes in hormone levels, reproductive tissues, or germ or support cells. These parameters can only be evaluated in vivo.
While animal testing cannot be avoided at present, there are various steps that should be taken immediately to improve the efficacy and clinical relevance of the testing and reporting of data. First, the general protocol for testing should be reconsidered. The usual one-size-fits-all approach to toxicity testing should be scrapped in favor of integrative studies taking into account the differences in pharmacokinetics/ pharmacodynamics of the drug (if known), the intended target population (the age and disease background of the patients may be relevant to the toxicity), the effects of structurally and mechanistically similar drugs, and any information that can be obtained from in silico studies (high-throughput testing of the compound's predicted structure for interactions with characterized receptors and biomacromolecules). It may also be necessary to change the endpoints of studies. Instead of assessing sperm at a single time point (at a pre-specified time after a single dose, or at the end of a chronic study), it would likely be better to collect sperm at several different time points. Collection of multiple samples (including collection on more than 1 day prior to starting treatment) is particularly important for clinical trials given the high variability in human sperm production [111, 114] . Additional testing to confirm recovery would provide helpful information for counseling patients on the long-term adverse effects.
Perhaps the most important changes would be those made to the reporting of the findings. Although the FDA receives the full results of the pre-clinical toxicity studies and clinical safety studies, including the numbers of animals used for preclinical testing (or patients included in a clinical trial), this information is frequently lacking from the drug labels in DailyMed. A clear statement of the number of individuals evaluated and the number or percentage of these affected by each adverse effect would help to interpret the findings. It would also be useful for this information to specify the extent of the adverse impact, such as the exact percentages of sperm with abnormal morphology, rather than a blanket statement indicating that there were morphological changes. This information would not need to appear on the main drug label included with the packaging of each drug, but should be linked online (with the link included in the printed information) so that the full details of the study are readily available from DailyMed.
Another point that is commonly lacking in both the DailyMed labels and the data in journal articles is the reversibility of the spermatotoxicity and time to recovery (if recovery is possible). This information is frequently missing for pre-clinical studies, largely because sperm are usually collected at a single time point, sometimes at necropsy. Although clinical trials are more likely to assess the long-term effects of a drug, the long-term reproductive outcomes are often not evaluated. This is partly because such endpoints are difficult to add to standard surveillance protocols because the collection of semen is more invasive and potentially associated with ethical concerns, compared to physical examinations and blood collection.
Finally, computing power has been rapidly increasing during the past few decades, and research studies are helping to illuminate the molecular basis of various physiological processes. Therefore, efforts should be made to better understand the signaling and cellular interactions involved in normal fertility to permit in silico modeling of possible interference by investigational drugs. This would inform confirmatory studies to be performed in vitro on human sperm or iPSC-derived or other sources of germ cells, could suggest biomarkers to allow for more sensitive detection of effects in vivo (in animals and/ or humans), and would predict the toxicity likely to be encountered. As in silico modeling continues to improve, it may become possible to evaluate the interactions of various agents and various pathways simultaneously and to combine such findings with those from in vitro and limited in vivo studies for an integrated approach, more accurately predicting the effects in humans [115, 116] .
Until toxicity testing is optimized, it is necessary to consider that there is a potential for human risk whenever there is a positive finding of spermatotoxicity in nonclinical or pre-clinical studies for one or more endpoints. The details of the findings and the level of evidence should be included to help physicians and/or pharmacists inform their patients of the risks of specific treatments to their fertility.
Conclusion
Our present findings illustrate the status of male reproductive toxicity testing and provide a useful reference about the FDAapproved drugs known to affect animal spermatogenesis and how these findings correlate with the human clinical setting. These findings emphasize the need for a better understanding of basic sperm biology to allow for the prediction of spermatotoxicity based on a drug's effects (both targeted and nonspecific). A greater understanding of the normal variations in the sperm of men of various ages and different health status would also help to understand what should be considered abnormal during clinical trials and long-term surveillance. In addition, since the predictive value of animal testing is so low, there is a need for a more comprehensive evaluation of the effects on human sperm in vitro and continued development of in silico and alternative in vitro studies so that potential changes can be estimated before the initiation of human clinical trials. Such an understanding could be used to determine whether the normal observations carried out during clinical trials should be increased or altered to better detect changes.
There are several limitations to this review that should be noted. First, only single-ingredient, FDA-approved drugs indicated for human use that were included in the DailyMed database were analyzed in this study. Although this database is the largest of its type, there are still a few drugs for which information is missing. In addition, all over-the-counter medications, including vitamins, supplements, and herbal/alternative medications, were excluded because the toxicity information on these agents is typically lacking. However, these excluded agents may be associated with spermatotoxicity, either when taken alone or by potentiating the effects of other drugs. The present investigation also focused on the direct effects of drugs on spermatozoa, which represents only a small aspect of male fertility. In addition, there may have been some reporting or publication bias for the databases. However, whenever possible, only large and well-designed clinical trials were included for the PubMed data, and it is noted whenever small-scale studies or case reports are cited in the tables. For the DailyMed database, the data sources are often unclear, so the accuracy of the data is also unclear.
Despite these limitations, the present data are useful in that they provide a comprehensive overview of the prescription drugs that affect animal spermatogenesis, as well as an illustration of the relatively poor performance of animal testing for predicting spermatotoxicity. Several suggestions have been made which might improve the testing and reporting of the data, hopefully leading to better patient care.
